Rankings
▼
Calendar
AMRX Q3 2025 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMRX
Amneal Pharmaceuticals, Inc.
$4B
Q3 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$785M
+11.7% YoY
Gross Profit
$274M
34.9% margin
Operating Income
-$117,000
-0.0% margin
Net Income
$2M
0.3% margin
EPS (Diluted)
$0.01
QoQ Revenue Growth
+8.3%
Cash Flow
Operating Cash Flow
$118M
Free Cash Flow
$103M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$3.6B
Total Liabilities
$3.7B
Stockholders' Equity
-$109M
Cash & Equivalents
$201M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$785M
$702M
+11.7%
Gross Profit
$274M
$270M
+1.6%
Operating Income
-$117,000
$89M
-100.1%
Net Income
$2M
-$156,000
+1618.6%
Revenue Segments
Amneal Specialty Pharma Segment
$125M
100%
Geographic Segments
Specialty Segment
$125M
100%
← FY 2025
All Quarters
Q4 2025 →